05:13 PM EST, 12/16/2024 (MT Newswires) -- Merck ( MRK ) said Monday it is discontinuing the clinical development programs for vibostolimab and favezelimab.

Merck ( MRK ) said it is ending Phase 3 trials in the KeyVibe program, which assesses the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung cancer, based on the recommendation of an independent Data Monitoring Committee.

Separately, the company said it will cancel the favezelimab program and will end enrollment in a phase 3 trial assessing the fixed-dose combination of favezelimab and pembrolizumab in people with relapsed or refractory classical Hodgkin lymphoma.

The company said while there are no safety concerns regarding this fixed-dose combination, the decision was made after a thorough evaluation of data from the favezelimab clinical program.

The focus will now shift to prioritizing the development of other candidates in its comprehensive and diversified oncology pipeline, according to the company.